Cargando…
Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
Autores principales: | Suraweera, Amila, Duff, Alex, Adams, Mark N., Jekimovs, Christian, Duijf, Pascal H. G., Liu, Cheng, McTaggart, Matthew, Beard, Sam, O’Byrne, Kenneth J., Richard, Derek J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076266/ https://www.ncbi.nlm.nih.gov/pubmed/33500542 http://dx.doi.org/10.1038/s41416-020-01242-4 |
Ejemplares similares
-
Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
por: Suraweera, Amila, et al.
Publicado: (2020) -
COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target
por: Suraweera, Amila, et al.
Publicado: (2021) -
Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising
por: Jekimovs, Christian, et al.
Publicado: (2014) -
COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks
por: Suraweera, Amila, et al.
Publicado: (2021) -
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)